The global skin cancer treatment market revenue was around US$ 7.72 billion in 2022 and is estimated to reach US$ 14.5 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.3% during the forecast period from 2023 to 2031.
Skin cancer is the abnormal growth of skin cells, most often growing on skin exposed to the sun. Skin cancer generally appears in sun-exposed regions of the body, such as the face, scalp, ears, lips, chest, neck, arms, and hands. But it can also grow on body parts that are infrequently exposed to sunlight, such as the palms, the skin just below the toenail or finger, and the genital region. All skin tones, including those with darker complexions, are susceptible to developing skin cancer.
Market Driving Factors
Increased product approvals by regulatory bodies for the treatment of skin cancer also contribute to boosting the market's expansion. For instance, in February 2021, the FDA announced the approval of the first immunotherapy product, PD-1 inhibitor Libtayo to treat basal cell carcinoma, which has a greater chance of success rate than the previously utilized hedgehog pathway inhibitor (HHI).
The surge in initiatives taken by government and market players involved in the development and manufacturing of innovative therapeutics in the healthcare sector is boosting market growth.
The high price of immunotherapy and chemotherapy, as well as the adverse consequences of these treatments may hamper the market growth.
Regional Analysis
North America dominated the market and is expected to continue its dominance over the forecast period. This can be attributed to the higher prevalence of skin cancer in the United States combined with more increased penetration of cancer drugs in the nation. In addition, it is anticipated that the inclination of major industry participants to introduce cutting-edge skin cancer treatments will favorably impact the market expansion.
Asia-Pacific is predicted to witness significant growth in the market. This is due to the surge in the initiative taken by the government to create healthcare infrastructure, increase the awareness among people about the availability of skin care treatments, and rise in research activities.
Segmentation Insights
Type Insight
The melanoma segment dominated the market. This can be attributed to the increase in awareness among the population concerning skin cancer and technical advancement in the healthcare sector to treat melanoma.
The non-melanoma segment is expected to dominate the market. This is due to the surge in the prevalence of non-melanoma kind of skin cancer and the rise in the number of product approvals for the treatment of non-melanoma type of skin cancer.
Therapy Insight
The immunotherapy segment dominated the market. This can be attributed to the effectiveness of immunotherapy the minor side effects associated with it and the increase in the initiative taken by the government to create healthcare infrastructure.
Prominent Companies
Segmentation Outline
The global skin cancer treatment market segmentation focuses on Distribution Channel, Type, Therapy, and Region.
By Distribution Channel
By Type
By Therapy
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL SKIN CANCER TREATMENT MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: SKIN CANCER TREATMENT MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL SKIN CANCER TREATMENT MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
5.1 OVERVIEW
5.2 HOSPITALS PHARMACIES
5.3 DRUG STORES AND RETAIL PHARMACIES
5.4 ONLINE PROVIDERS
6 GLOBAL SKIN CANCER TREATMENT MARKET, BY TYPE
6.1 OVERVIEW
6.2 MELANOMA
6.3 NON-MELANOMA
6.3.1 BASAL CELL CARCINOMA
6.3.2 SQUAMOUS CELL CARCINOMA
6.3.3 OTHERS
7 GLOBAL SKIN CANCER TREATMENT MARKET, BY THERAPY
7.1 OVERVIEW
7.2 IMMUNOTHERAPY
7.3 TARGETED THERAPY
7.4 CHEMOTHERAPY
8 GLOBAL SKIN CANCER TREATMENT MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3. 1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL SKIN CANCER TREATMENT MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 LEO PHARMA
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 BRISTOL-MYERS SQUIBB
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 SUN PHARMACEUTICAL INDUSTRIES LTD
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 GLAXOSMITHKLINE PLC
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 REGENERON PHARMACEUTICALS INC
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 F. HOFFMANN-LA ROCHE
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 NOVARTIS AG
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 PFIZER INC
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 AMGEN INC
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 MERCK KGAA
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved